한글목차

세계의 치료제 시장은 2024년 4억 8,521만 달러에서 2030년까지 7억 6,272만 달러로, CAGR 7.83%로 성장할 것으로 예측됩니다.

치료제는 기존의 대증요법을 넘어 질병의 근본 원인을 표적화하여 영구적인 해결을 위해 고안된 진보된 의료 개입을 의미합니다. 시장 확대는 주로 만성질환 및 희귀질환으로 인한 전 세계적인 부담 증가, 유전자 편집 및 세포 치료와 같은 생명공학 플랫폼의 지속적인 발전, 그리고 신약 후보물질 개발 파이프라인을 가속화하는 R&D 투자 증가에 의해 주도되고 있습니다.

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 치료제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(생물학적 제제, 유전자 치료, 세포 치료)
  • 적응증별(암, 근골격계 질환, 신경퇴행성 질환, 희귀질환, C형 간염, 기타)
  • 최종사용자별(제약회사, 학술·연구기관, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Pfizer, Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Bluebird bio, Inc.
• Novartis AG
• Spark Therapeutics, Inc.
• Gilead Sciences, Inc.
• Sarepta Therapeutics, Inc.
• Vertex Pharmaceuticals Incorporated
• Alnylam Pharmaceuticals, Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Curative Therapeutics Market will grow from USD 485.21 Million in 2024 to USD 762.72 Million by 2030 at a 7.83% CAGR. Curative therapeutics encompass advanced medical interventions engineered to permanently resolve diseases by targeting and correcting their fundamental causes, moving beyond conventional symptomatic management. The market's expansion is primarily driven by the substantial global burden of chronic and rare diseases, coupled with continuous advancements in biotechnological platforms such as gene editing and cell therapies, and increasing investments in research and development accelerating the pipeline of novel candidates.

Key Market Drivers

Breakthroughs in cell and gene therapy represent a paramount driver for the global curative therapeutics market, fundamentally reshaping treatment paradigms for previously intractable diseases. These advanced modalities offer potential for one-time cures by correcting underlying genetic defects or harnessing the body's immune system to combat illness. The accelerating pace of innovation, evidenced by novel therapeutic approvals, signifies platform maturation. According to RegMedNet, in May 2025, "FDA-Approved Cell and Gene Therapies", the US Food and Drug Administration approved nine cell and gene therapy products in 2024, targeting conditions such as cancer, hemophilia B, and aromatic L-amino acid decarboxylase deficiency. This demonstrates expanding regulatory confidence and the broader scope of conditions amenable to these revolutionary approaches.

Key Market Challenges

A significant challenge impeding the expansion of the Global Curative Therapeutics Market is the high upfront cost associated with developing and delivering these complex therapies. This factor directly creates affordability concerns for healthcare systems and patients, consequently limiting widespread access and consistent reimbursement for treatments, even those demonstrating high efficacy. Such substantial costs strain national healthcare budgets and individual patient finances, thereby hindering the broader adoption necessary for robust market growth.

Key Market Trends

Increased Payer Acceptance of Value-Based Pricing for Curative Therapies is significantly influencing the global curative therapeutics market by providing new frameworks for drug reimbursement. This trend addresses the substantial upfront costs of these advanced treatments by linking payment to predefined clinical outcomes or long-term efficacy, thereby reducing financial risk for healthcare systems and fostering greater market access. This approach encourages a shift from volume-based to value-based healthcare, where the economic burden is shared, and therapies are evaluated on their demonstrated patient benefit.

Key Market Players

• Pfizer, Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Bluebird bio, Inc.
• Novartis AG
• Spark Therapeutics, Inc.
• Gilead Sciences, Inc.
• Sarepta Therapeutics, Inc.
• Vertex Pharmaceuticals Incorporated
• Alnylam Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Curative Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Curative Therapeutics Market, By Type:

• Biology Modifying Drugs
• Gene Therapies
• Cell Therapies

Curative Therapeutics Market, By Indication:

• Cancer
• Musculoskeletal Disorders
• Neurodegenerative Diseases
• Rare Diseases
• Hepatitis C
• Others

Curative Therapeutics Market, By End User:

• Pharmaceutical Companies
• Academic & Research Institutions
• Others

Curative Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Curative Therapeutics Market.

Available Customizations:

Global Curative Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Curative Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Biology Modifying Drugs, Gene Therapies, Cell Therapies)
  • 5.2.2. By Indication (Cancer, Musculoskeletal Disorders, Neurodegenerative Diseases, Rare Diseases, Hepatitis C, Others)
  • 5.2.3. By End User (Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Curative Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Curative Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Curative Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Curative Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Curative Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Curative Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Curative Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Curative Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Curative Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Curative Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Curative Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Curative Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Curative Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Curative Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Curative Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Curative Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Curative Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Curative Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Curative Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Curative Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. South America Curative Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Curative Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Curative Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Curative Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Curative Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc
• 15.3. Sanofi S.A.
• 15.4. Bluebird bio, Inc.
• 15.5. Novartis AG
• 15.6. Spark Therapeutics, Inc.
• 15.7. Gilead Sciences, Inc.
• 15.8. Sarepta Therapeutics, Inc.
• 15.9. Vertex Pharmaceuticals Incorporated
• 15.10. Alnylam Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer